Finance

Lists
Q2 2027 earnings • 6:00 AM tomorrow
See details
4502:TYO
Takeda Pharmaceutical Co Ltd
¥6,307.00
0.00%
(0.00) 1D
Oct 28, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4502...
Mkt. cap
10.11T
Avg. vol.
4.48M
Volume
0.00
Dividend
3.17%
Quarterly dividend
¥50
Ex-dividend date
Sep 29, 2026
52-wk high
¥6,500
52-wk low
¥4,102
EPS
-¥103
Shares outstanding
784.48M
No. of employees
47K
Mkt. cap
10.11T
Avg. vol.
4.48M
Volume
0.00
Dividend
3.17%
Quarterly dividend
¥50
Ex-dividend date
Sep 29, 2026
52-wk high
¥6,500
52-wk low
¥4,102
EPS
-¥103
Shares outstanding
784.48M
No. of employees
47K
News stories
From web sources and news partners
Profile
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. In 2026, Julie Kim was noted in a news item as "CEO-elect". Wikipedia
About Takeda Pharmaceutical Co Ltd
CEOChristophe Weber | Christophe Weber
Employees47K
FoundedJun 12, 1781
Headquarters-
SectorPharmaceutical industry
Websitetakeda.com
Next call in 10:26:37
Tomorrow, 6:00 AM
Fiscal period
Q2 2027
- / -
Revenue / Est. (JPY)
- / 1.16T
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.11T
1.19T
1.09T
1.22T
Cost of goods sold
380.06B
401.15B
453.33B
406.68B
Cost of revenue
380.06B
401.15B
453.33B
406.68B
Research and development expenses
161.48B
175.23B
187.96B
167.40B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
253.55B
282.78B
291.96B
286.51B
Operating expense
562.57B
661.30B
519.65B
612.60B
Total operating expenses
942.63B
1.06T
972.98B
1.02T
Operating income
170.17B
129.25B
121.56B
200.62B
Other non operating income
77.96B
-197.22B
181.53B
-28.14B
EBT including unusual items
28.17B
133.86B
-455.02B
162.72B
EBT excluding unusual items
128.86B
114.17B
71.49B
161.92B
Income tax expense
39.90B
30.13B
-86.62B
49.46B
Effective tax rate
141.64%
22.51%
19.04%
30.40%
Other operating expenses
16.12B
67.13B
-64.27B
53.17B
Net income
-11.80B
103.64B
-368.47B
113.20B
Net profit margin
-1.06%
8.70%
-33.66%
9.28%
Earnings per share
-
-
-
-
Interest and investment income
43.92B
181.35B
-
24.61B
Interest expense
-161.10B
-
-239.63B
-35.70B
Net interest expenses
-117.18B
181.35B
-239.63B
-11.09B
Depreciation and amortization charges
-
-
-
-
EBITDA
355.15B
319.89B
192.73B
363.66B
Gain or loss from assets sale
303.00M
358.00M
1.46B
-6.00B
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps